Jones Trading Reiterates Buy Rating on Capricor Therapeutics (CAPR) as FDA review resumed
Tweet Send to a Friend
Jones Trading analyst Catherine Novack reiterated a Buy rating and $51.00 price target on Capricor Therapeutics (NASDAQ: CAPR)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
